Cabazitaxel cellulose nanoparticle - Triphase Accelerator Corporation

Drug Profile

Cabazitaxel cellulose nanoparticle - Triphase Accelerator Corporation

Alternative Names: CBZed-Nano™

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Triphase Accelerator Corporation
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioma; Prostate cancer

Most Recent Events

  • 26 Apr 2016 Results from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) ,
  • 22 Apr 2016 Triphase Accelerator Corporation enters into the collaboration with the Ontario Institute for Cancer Research (OICR)
  • 18 Apr 2016 Preclinical trials in Prostate cancer and Glioma in Canada (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top